These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

714 related items for PubMed ID: 8161290

  • 1. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
    McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH.
    Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
    [Abstract] [Full Text] [Related]

  • 2. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
    McDougle CJ, Goodman WK, Leckman JF, Barr LC, Heninger GR, Price LH.
    J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
    [Abstract] [Full Text] [Related]

  • 3. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
    Bogetto F, Bellino S, Vaschetto P, Ziero S.
    Psychiatry Res; 2000 Oct 30; 96(2):91-8. PubMed ID: 11063782
    [Abstract] [Full Text] [Related]

  • 4. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH.
    Arch Gen Psychiatry; 2000 Aug 30; 57(8):794-801. PubMed ID: 10920469
    [Abstract] [Full Text] [Related]

  • 5. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H, Jia F, Han H, Wang S, Guo G, Quan D, Li G, Huang H.
    Eur Neuropsychopharmacol; 2019 Mar 30; 29(3):397-404. PubMed ID: 30595354
    [Abstract] [Full Text] [Related]

  • 6. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L.
    Am J Psychiatry; 1999 Sep 30; 156(9):1409-16. PubMed ID: 10484953
    [Abstract] [Full Text] [Related]

  • 7. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF.
    Mol Psychiatry; 2006 Jul 30; 11(7):622-32. PubMed ID: 16585942
    [Abstract] [Full Text] [Related]

  • 8. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
    McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH.
    J Clin Psychiatry; 1995 Nov 30; 56(11):526-8. PubMed ID: 7592506
    [Abstract] [Full Text] [Related]

  • 9. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L.
    Eur Neuropsychopharmacol; 2005 Jan 30; 15(1):69-74. PubMed ID: 15572275
    [Abstract] [Full Text] [Related]

  • 10. Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder.
    Husted DS, Shapira NA, Murphy TK, Mann GD, Ward HE, Goodman WK.
    J Psychiatr Res; 2007 Jan 30; 41(3-4):332-7. PubMed ID: 16860338
    [Abstract] [Full Text] [Related]

  • 11. [Efficacy of fluvoxamine combined with extended-release methylphenidate on treatment-refractory obsessive-compulsive disorder].
    Zheng H, Jia F, Guo G, Quan D, Li G, Huang H.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Nov 28; 43(11):1230-1235. PubMed ID: 30643068
    [Abstract] [Full Text] [Related]

  • 12. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
    Askari N, Moin M, Sanati M, Tajdini M, Hosseini SM, Modabbernia A, Najand B, Salimi S, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S.
    CNS Drugs; 2012 Oct 01; 26(10):883-92. PubMed ID: 22873680
    [Abstract] [Full Text] [Related]

  • 13. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study.
    Arabzadeh S, Shahhossenie M, Mesgarpour B, Rezaei F, Shalbafan MR, Ghiasi Z, Akhondzadeh S.
    Hum Psychopharmacol; 2017 Jul 01; 32(4):. PubMed ID: 28485008
    [Abstract] [Full Text] [Related]

  • 14. [Treatment-refractory OCD from the viewpoint of obsessive-compulsive spectrum disorders: impact of comorbid child and adolescent psychiatric disorders].
    Kano Y.
    Seishin Shinkeigaku Zasshi; 2013 Jul 01; 115(9):990-6. PubMed ID: 24228477
    [Abstract] [Full Text] [Related]

  • 15. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.
    McDougle CJ, Goodman WK, Leckman JF, Holzer JC, Barr LC, McCance-Katz E, Heninger GR, Price LH.
    Am J Psychiatry; 1993 Apr 01; 150(4):647-9. PubMed ID: 8465885
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.
    Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS.
    Arch Gen Psychiatry; 1989 Jan 01; 46(1):36-44. PubMed ID: 2491940
    [Abstract] [Full Text] [Related]

  • 17. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM.
    J Clin Psychiatry; 2003 Jun 01; 64(6):640-7. PubMed ID: 12823077
    [Abstract] [Full Text] [Related]

  • 18. Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder.
    McDougle CJ, Goodman WK, Price LH.
    J Clin Psychiatry; 1994 Mar 01; 55 Suppl():24-31. PubMed ID: 7521326
    [Abstract] [Full Text] [Related]

  • 19. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
    Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S.
    J Psychiatr Res; 2013 Feb 01; 47(2):175-80. PubMed ID: 23063327
    [Abstract] [Full Text] [Related]

  • 20. L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
    Nematizadeh M, Ghorbanzadeh H, Moghaddam HS, Shalbafan M, Boroon M, Keshavarz-Akhlaghi AA, Akhondzadeh S.
    Psychiatry Clin Neurosci; 2023 Sep 01; 77(9):478-485. PubMed ID: 37169515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.